Bolt Biotherapeutics (BOLT) finance SVP awarded 8,000 options and buys shares

Rhea-AI Filing Summary

Bolt Biotherapeutics officer reports small share purchase and new option grant. Senior VP, Finance and PAO Sarah Nemec bought 125 shares of common stock on 12/05/2025 at $4.607 per share under the company’s Employee Stock Purchase Plan, bringing her direct holdings to 1,415 shares.

On 01/28/2026 she received an employee stock option for 8,000 shares at a $6.71 exercise price. This option is scheduled to vest in equal monthly installments, with 1/36 of the shares vesting after each month of continuous service following January 1, 2026, and expires on January 27, 2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nemec Sarah

(Last) (First) (Middle)

C/O BOLT BIOTHERAPEUTICS, INC.

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior VP, Finance and PAO

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/05/2025		P(1)		125	A	$4.607	1,415	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$6.71	01/28/2026		A		8,000		(2)	01/27/2036	Common Stock	8,000	$0	8,000	D

Explanation of Responses:

1. These shares were acquired under the Issuer's Employee Stock Purchase Plan , in transactions that were exempt under Rule 16b-3(c).

2. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2026.

	/s/ William P. Quinn, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Sarah Nemec report at Bolt Biotherapeutics (BOLT)?

Sarah Nemec reported buying 125 Bolt Biotherapeutics common shares and receiving an option grant for 8,000 shares. The purchase used the Employee Stock Purchase Plan, while the options provide future purchase rights subject to vesting and a $6.71 exercise price.

How many Bolt Biotherapeutics (BOLT) shares does Sarah Nemec now hold directly?

After the reported transactions, Sarah Nemec directly holds 1,415 shares of Bolt Biotherapeutics common stock. This figure reflects her 125-share purchase on December 5, 2025 through the Employee Stock Purchase Plan added to her previously reported holdings.

What are the key terms of Sarah Nemec’s 8,000-share stock option at Bolt Biotherapeutics (BOLT)?

The employee stock option covers 8,000 Bolt Biotherapeutics shares at a $6.71 exercise price and expires January 27, 2036. Vesting occurs in 36 equal monthly installments, with 1/36 vesting after each month of continuous service following January 1, 2026.

How were the 125 Bolt Biotherapeutics (BOLT) shares acquired by Sarah Nemec?

The 125 shares were acquired under Bolt Biotherapeutics’ Employee Stock Purchase Plan in a transaction priced at $4.607 per share. The filing notes these purchases were exempt from short-swing profit rules under Rule 16b-3(c), reflecting a routine employee plan participation.

What is Sarah Nemec’s role at Bolt Biotherapeutics (BOLT) according to the Form 4?

Sarah Nemec is identified as an officer of Bolt Biotherapeutics, serving as Senior VP, Finance and Principal Accounting Officer. Her status as an executive makes her transactions reportable, providing transparency into insider equity ownership and incentive alignment with shareholders.

How does the vesting schedule work for Sarah Nemec’s Bolt Biotherapeutics stock option?

The option vests monthly over three years, with 1/36 of the 8,000 shares vesting after each completed month of continuous service following January 1, 2026. This structure ties the benefit to her ongoing employment with Bolt Biotherapeutics over the vesting period.